The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130

Background The protease BACE1 is a major drug target for Alzheimer’s disease, but chronic BACE1 inhibition is associated with non-progressive cognitive worsening that may be caused by modulation of unknown physiological BACE1 substrates. Methods To identify in vivo-relevant BACE1 substrates, we appl...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular neurodegeneration 2023-02, Vol.18 (1), p.13-20, Article 13
Main Authors:	Müller, Stephan A., Shmueli, Merav D., Feng, Xiao, Tüshaus, Johanna, Schumacher, Neele, Clark, Ryan, Smith, Brad E., Chi, An, Rose-John, Stefan, Kennedy, Matthew E., Lichtenthaler, Stefan F.
Format:	Article
Language:	English
Subjects:	Acids Alliances Alzheimer Disease - drug therapy Alzheimer's disease Amyloid Precursor Protein Secretases Animals Aspartic Acid Endopeptidases Biomarkers Biomedical and Life Sciences Biomedicine Cerebrospinal fluid Clinical trials Cognitive ability Computer software industry Cytokine Receptor gp130 - therapeutic use Cytokines Drug dosages Glycoprotein gp130 Humans IL-6 receptor subunit beta IL-6R Inflammation Interleukin 6 Mice Molecular Medicine Monkeys & apes Nerve Tissue Proteins Neurodegenerative diseases Neurology Neurons Neurosciences Peptides Pharmacodynamics Physiological aspects Proteases Proteins Proteomics Research Article Scientific equipment and supplies industry Secretase Shedding Therapeutic targets Trans-signaling VCAM1 β-Site APP-cleaving enzyme 1 β-Site APP-cleaving enzymes
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!